GSK-364735

DB13119InvestigationalSmall molecule

GSK-364735 (Naphthyridinone) has been used in trials studying the treatment of HIV-1 Infection and Infection, Human Immunodeficiency Virus.

Chemical structure of GSK-364735
Mechanism
Curator reviewed
Formula / weight
C19H18FN3O4 · 371.368 g/mol (avg)
Also known as
Naphthyridinone
Code names
GSK-364735 · S-364735 · S/GSK-364735

Resolves to

Compound
UNIISXN0KXT60SCAS863434-13-3ChEMBLCHEMBL1256978PubChem54718859
Structure
InChIKeyQWLNINWUBHHOLU-UHFFFAOYSA-NSMILESCN1C(=O)C(C(=O)NCCO)=C(O)C2=NC=C(CC3=CC=C(F)C=C3)C=C12
Targets
Q7ZJM1polP04585gag-polP21554CNR1P34972CNR2

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with GSK-364735, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In